STING1 and neoplasm: Additionally, overcoming the technical and biological challenges inherent in effectively activating the cGAS-STING pathway without triggering excessive or detrimental inflammation and maintaining drug stability and activity within the complex and often immunosuppressive tumor microenvironment remains paramount 103, 106.